迈威生物(02493.HK)9MW5211注射液临床试验申请获国家药监局批准

阿斯达克财经
Aug 03

迈威生物-B(02493.HK) 公布,收到国家药品监督管理局核准签发的《药物临床试验批准通知书》,9MW5211注射液用于原发性胆汁性胆管炎(PBC)适应症的临床试验申请获得批准。此前,其用于炎症性肠病(IBD)适应症的临床试验申请已分别获得国家药品监督管理局批准和FDA许可,用于多发性硬化(MS)、1型糖尿病(T1DM)和白癜风适应症的临床试验申请已获得国家药品监督管理局批准;公司亦在积极推进...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10